4 completed, 1 withdrawn. 5 Phase 1, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Completed 4, Withdrawn 1 |
| Phase 2 | 5 | Completed 4, Withdrawn 1 |
Follow Stage III Rectal Cancer: new trials by email Literature Review of Stage III Rectal Cancer trials Research Report on Stage III Rectal Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Altered Chemotherapy Sequencing During Neoadjuvant Therapy for Patients With Stage II or III Rectal Adenocarcinoma Capecitabine, 5-FU, Leucovorin - Stage II Rectal Cancer, Stage III Rectal Cancer | Phase 1 / Phase 2 | Withdrawn | University of Texas Southwestern Medical Center | 2011-03-01 | 2020-08-20 | |
| Pertuzumab and Cetuximab in Treating Patients With Previously Treated Locally Advanced or Metastatic Colorectal Cancer pertuzumab, cetuximab, irinotecan hydrochloride - Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 17 | 2007-10-01 | 2015-03-31 |
| Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer erlotinib hydrochloride, cetuximab, bevacizumab - Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Adenoid Cystic Carcinoma of the Oral Cavity | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 66 | 2005-01-01 | 2014-06-11 |
| Oxaliplatin, Fluorouracil, and External-Beam Radiation Therapy Followed by Surgery in Treating Patients With Locally Advanced Cancer of the Rectum oxaliplatin, fluorouracil, external beam radiation therapy - Adenocarcinoma of the Rectum, Stage II Rectal Cancer | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 24 | 2000-07-01 | 2013-01-16 |
| SU5416 and Irinotecan in Treating Patients With Advanced Colorectal Cancer irinotecan hydrochloride, semaxanib, laboratory biomarker analysis - Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 68 | 2000-03-01 | 2013-01-23 |
Rectal Neoplasms (5) · Colonic Neoplasms (3) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Renal Cell (1) · Esthesioneuroblastoma, Olfactory (1) · Pancreatic Neoplasms (1) · Salivary Gland Neoplasms (1) · Squamous Cell Carcinoma of Head and Neck (1)
Colorectal Neoplasms (5) · Digestive System Diseases (5) · Digestive System Neoplasms (5) · Gastrointestinal Diseases (5) · Gastrointestinal Neoplasms (5) · Intestinal Diseases (5) · Intestinal Neoplasms (5) · Neoplasms (5) · Neoplasms by Site (5) · Rectal Diseases (5) · Colonic Diseases (3) · Adenocarcinoma (1) · Bronchial Neoplasms (1) · Carcinoma (1) · Carcinoma, Bronchogenic (1)
Cetuximab (2) · Fluorouracil (2) · Irinotecan (2) · Oxaliplatin (2) · 2C4 antibody (1) · Bevacizumab (1) · Capecitabine (1) · Erlotinib Hydrochloride (1) · Gene Expression Profiling (1) · Immunohistochemistry (1) · In Situ Hybridization, Fluorescence (1) · Leucovorin (1) · Polymerase Chain Reaction (1) · Radiation (1) · Semaxinib (1)
National Cancer Institute (NCI) (4) · University of Texas Southwestern Medical Center (1)
United States (5)
Alain Mita (1) · David Ryan (1) · James Abbruzzese (1) · Kimmie Ng (1)
N01CM17003 (1), P30CA054174 (1), U01CA062490 (1), U01CA069853 (1), U10CA031946 (1)